BSECompany Update25 Aug 2026 · 25 Aug 2026, 04:51 pm

Intimation of Schedule of the Investors/Analysts Meet

Akums Drugs and Pharmaceuticals Ltd · 544222

✦ AI Summary

Akums Drugs and Pharmaceuticals Ltd has informed about its participation in an investor/analysts meet on 2nd September 2026 at Hyatt, Santacruz, Mumbai. The meet is part of the India Dialogue 2026 and will start at 02:00 PM (IST). No unpublished price sensitive information will be shared during the meet.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Attachments (1)

📄

9b0f1271-56ec-412a-a7df-7189d27553c1.pdf

pdf

Download →
View document text
Ref: Akums/Exchange/2026-27/47 August 25, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Intimation of Schedule of the Investors/Analysts Meet Respected Sir/Ma’am, This is to inform you that pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals Limited (“the Company”) will participate in the below scheduled investor/analysts meet: S. No. Particulars of Meet Date & Time of Type of Meet Location / Mode Meeting of Meeting 1 Ashwamedh – Elara 2nd September, Group Meet Hyatt, Santacruz India Dialogue 2026 2026; starts at East, Mumbai/ 02:00 PM (IST) Physical Further, no unpublished price sensitive information pertaining to the Company will be shared during the meet with Analysts/Investors. Please note that the above may subject to change due to exigencies on the part of Investors/analysts or the Company. A copy of this disclosure is being updated on website of the Company at www.akums.in This is for your information and records. For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer